



November 9, 2017

## **NanoString Highlights Record Number of nCounter-Based Research Abstracts at the 2017 Annual Meeting of the Society of Immunotherapy of Cancer (SITC)**

*45 Abstracts Demonstrate the Value of the nCounter Platform for Immuno-Oncology Research*

*Studies Indicate the Clinical Relevance of the Tumor Inflammation Signature for Multiple Immunotherapies*

SEATTLE, Nov. 09, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in understanding immune response and cancer immunotherapy using the nCounter® platform that will be presented at the 32nd Annual Meeting of the Society of Immunotherapy of Cancer (SITC).

"The scope of nCounter-based research being presented at this year's SITC conference demonstrates our scientific and commercial momentum in immuno-oncology," said Alessandra Cesano, chief medical officer of NanoString. "In addition, several abstracts outline the unique capabilities of our Digital Spatial Profiling technology to characterize the tumor and its microenvironment to inform cancer research and drug development."

At least 45 abstracts using NanoString's nCounter platform will be presented at the SITC Annual Meeting, being held in National Harbor, Maryland, Nov. 8-12, 2017. The research being presented spans a wide breadth of applications including biomarker development, assessing the biology of immune responsiveness and resistance, and digital pathology. They include biomarker studies covering 21 therapeutic agents, as single agents or in combination.

Nineteen studies used NanoString's PanCancer Series of panels to explore biomarkers associated with response to immunotherapy. Fourteen of these studies incorporate NanoString's best-selling PanCancer Immune Profiling Panel. An additional five studies incorporating both early access and commercial versions of NanoString's new PanCancer IO 360™ Panel. The PanCancer IO 360 Panel assays key pathways from the tumor, the microenvironment and the immune system and includes more than 20 signatures that are potentially associated with therapeutic response to novel therapeutic agents with "matched" mechanisms of action. Three additional studies incorporate the nCounter Hallmarks of Cancer suite of gene expression panels, which includes three panels covering Cancer Immune Profiling, Cancer Pathways, and Cancer Progression.

The PanCancer IO 360 Panel studies provide initial evidence of positive association between the Tumor Inflammation Signature scores and clinical response to different immuno-oncology agents including nivolumab, ipilimumab, pembrolizumab and entinostat. NanoString's Tumor Inflammation Signature (TIS) was recently described by Ayers, et al. (<https://www.jci.org/articles/view/91190>) and is included in the PanCancer IO360 panel. The Tumor Inflammation Signature measures the presence or absence of a peripherally suppressed adaptive immune response within the tumor.

Five studies cover the use of NanoString's Digital Spatial Profiling (DSP) platform in immuno-oncology research. DSP allows for digital quantification of protein from discrete regions of FFPE tissue in an automated and multiplex format. DSP will become widely available with the launch of a new instrument planned for late 2018, and in the meantime is available under a Technology Access Program.

Two studies cover the use of 3D Biology™ panels and demonstrate the utility of the nCounter platform. NanoString's 3-D Flow™ technology provides detailed molecular profiles of T cell populations, and enables unique, simultaneous analysis of high-plex protein and RNA data. 3D Biology and 3D Flow approaches can be used to characterize baseline immunological state and response to stimulation, which may be useful for profiling mechanisms of action or therapeutic response.

At the 2017 SITC Annual Meeting, NanoString will showcase its nCounter platform, IO360 Data Analysis, Digital Spatial Profiling and 3D Biology capabilities at booth #605.

NanoString will host a Digital Spatial Profiling Educational Session on Nov. 11, 2017, 12:45 - 1:45 p.m.

Below is a summary of abstracts co-authored by NanoString employees:

Abstract

#	Title	Hyperlink
05	A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand	<a href="https://www.sitcancer.org/2017/abstracts/titles/oral">https://www.sitcancer.org/2017/abstracts/titles/oral</a>
019	ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)	<a href="https://www.sitcancer.org/2017/abstracts/titles/oral">https://www.sitcancer.org/2017/abstracts/titles/oral</a>
P40	Deep proteomic and transcriptomic analysis of sorted T cells with a simple, integrated workflow	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P43	Assessment of Pharmacodynamic Effects of Immuno-Oncology Agents in Cynomolgus Monkeys using High-Content Gene Expression Profiling	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P64	Analytical Validation of Digital Spatial Profiling - a novel approach for multiplexed characterization of protein distribution and abundance in FFPE tissue sections	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P65	Spatially-resolved, multiplexed digital characterization of protein abundance in FFPE tissue sections: application in preclinical mouse models	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P66	Digital spatial profiling platform allows both spatially-resolved, multiplexed measurement of solid tumor and immune-associated protein distribution and abundance using a single FFPE tissue section	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P72	Analysis of biomarkers from a cohort of advanced melanoma patients previously exposed to immune checkpoint inhibition treated with entinostat (ENT) and pembrolizumab (PEMBRO).	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P73	First-in-human neoadjuvant study of the immunogenomic impact of the oral IDO inhibitor epacadostat (INCB024360) on the tumor microenvironment of advanced ovarian cancer	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P98	Immunological profiling of baseline and resected biopsies from locally/regionally advanced/recurrent melanoma treated with neoadjuvant combination ipilimumab (3mg/kg or 10mg/kg) and high dose IFN- $\alpha$ 2B	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P99	Biomarker analysis from the OpACIN trial (Neo-/adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma)	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P100	Pretreatment gene expression correlation with clinical response to pembrolizumab or nivolumab in metastatic melanoma	<a href="https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring">https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring</a>
P383	Molecular and immune characterization of melanoma metastases with heterogeneous PTEN expression	<a href="https://www.sitcancer.org/2017/abstracts/titles/mechanisms-resistance-immunotherapy">https://www.sitcancer.org/2017/abstracts/titles/mechanisms-resistance-immunotherapy</a>
P485	Use of the NanoString Gene Expression Profiling Platform to Capture the Immunological Status of the Leukemia Microenvironment	<a href="https://www.sitcancer.org/2017/abstracts/titles/tumor-microenvironment">https://www.sitcancer.org/2017/abstracts/titles/tumor-microenvironment</a>
P512	Deep immunoprofiling of rare T-cell populations from clinical samples	<a href="https://www.sitcancer.org/2017/abstracts/titles/late-breaking">https://www.sitcancer.org/2017/abstracts/titles/late-breaking</a>
P524	Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1	<a href="https://www.sitcancer.org/2017/abstracts/titles/late-breaking">https://www.sitcancer.org/2017/abstracts/titles/late-breaking</a>

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,700 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit [www.nanostring.com](http://www.nanostring.com).

### **Forward-Looking Statements**

*This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the capabilities of the company's current and future products and the timing of future product launches. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the impact of competition; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.*

NanoString, NanoString Technologies, the NanoString logo, 3D Biology, 3D Flow, nCounter, PanCancer IO360 and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contact:

**Doug Farrell**

Vice President, Investor Relations & Corporate Communications

[dfarrell@nanostring.com](mailto:dfarrell@nanostring.com)

**Phone: 206-602-1768**

Source: NanoString Technologies, Inc.

News Provided by Acquire Media